[管理者用] 最新ニュース(タブ)
サブ-ナビゲーション
information
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
[管理者用] 最新ニュース(タブ)
What’s new
Press Release
Investor Relations
Information
2025/06/04
Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
2025/05/29
Notice of the 23rd Annual General Meeting of Shareholders
(198KB)
2025/05/13
Notice of Changes in Representative Directors
(140KB)
2025/05/13
Notice Concerning Dividend from Surplus
(137KB)
2025/05/13
Consolidated Financial Results for the FY Ended March 31 2025
(478KB)
Read More
2025/06/04
Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
2024/06/27
Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/10/12
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
Read More
2025/05/29
Notice of the 23rd Annual General Meeting of Shareholders
(198KB)
2025/05/13
Notice of Changes in Representative Directors
(140KB)
2025/05/13
Notice Concerning Dividend from Surplus
(137KB)
2025/05/13
Consolidated Financial Results for the FY Ended March 31 2025
(478KB)
2025/05/01
(Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary
(233KB)
Read More
2024/05/02
Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
Read More
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box